The person depicted is a model used for illustrative purposes only.
It’s time to look again—in clinical trials, MENVEO demonstrated noninferior head-to-head immunogenicity data compared to Menactra in 11 to 18 year-olds and has the broadest age indication for MenACWY vaccination1
Vaccination may not protect all recipients.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.